BackPhaseBio Pharmaceuticals Overview

PhaseBio Pharmaceuticals Property, Plant & Equipment

Latest property, plant & equipment for PHAS: $11M.

Get informed when a big investor buys or sells

+ Follow
PPE
$10.54M
↓ 12.72% YoYΔ $-1.54M vs prior year quarter

Peer trimmed avg / median

Loading

PhaseBio Pharmaceuticals PPE History

Loading

PhaseBio Pharmaceuticals vs. peers: PPE Comparison

Loading

PhaseBio Pharmaceuticals PPE Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

PhaseBio Pharmaceuticals (PHAS) FAQ

As of the most recent data (June 2022), PHAS shows a PP&E of $11M. That compares with $12M in the prior-year period — down 12.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PHAS's PP&E is now $11M (was $12M) — a 12.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether PhaseBio Pharmaceuticals is outperforming or lagging.

Tracking PHAS's property, plant & equipment over time shows whether PhaseBio Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $11M That compares with $12M in the prior-year period — down 12.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this property, plant & equipment page, Stockcircle has PhaseBio Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect PP&E (currently $11M) with ownership activity and broader fundamentals.

PhaseBio Pharmaceuticals's PP&E is $11M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.